IOS Foundation is a Chagrin Falls, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spire Orthopedic Partners is a growing national partnership of orthopedic practices that provides the support, capital and operational resources physicians need to grow thriving practices for the future. As a management services organization, Spire provides the infrastructure for administrative operations that allows practices to operate at their highest level, so doctors can focus their efforts on what matters most – patient care. Rooted in the 100-plus-year legacy of its founding partners, the network spans the Northeast with 50 physicians, 450 employees and 10 locations from Connecticut to New York.
Nomad Health is the first digital marketplace for healthcare jobs, efficiently connecting quality clinicians with rewarding career opportunities and taking the busywork out of finding clinical work. We are a well-funded Series C startup backed by First Round Capital, RRE Ventures, .406 Ventures, Polaris Partners, Icon Ventures, and Kevin Ryan (founder of MongoDB, Zola, Gilt, and DoubleClick). The U.S. healthcare system is experiencing a staffing crisis. Employers spend $20 billion per year recruiting clinicians to provide care for patients around the country. Nomad replaces antiquated staffing agencies with modern technology to efficiently source, qualify, and hire medical talent on demand. Clinicians find better jobs with higher pay. Employers fill roles faster with higher quality care. Nomad is a fast growing team of technologists, creators, and industry experts passionate about modernizing healthcare staffing so doctors and nurses can get back to the work they do best: caring for others.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Flare Capital Partners invests and specializes exclusively in the healthcare technology sector. Working side-by-side, Flare Capital parlays strengths in business and medicine into action that supports entrepreneurs who provide innovative solutions and strive to be market leaders.